Genome Sequencing in Refractory Breast Cancer to Molecular Targeted Therapy and Young Breast Cancer

Samsung Medical Center1 site in 1 country350 target enrollmentSeptember 2012

ConditionsBreast Cancer

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Breast Cancer
Sponsor: Samsung Medical Center
Enrollment: 350
Locations: 1
Primary Endpoint: Number of Participants With Mutated Genes and/or Abnormal Gene expression and/or Different Immune signature That Affect to Treatment Outcome.
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to investigate and analyse genomic profiles in patient with breast cancer who failed standard treatment, refractory and young breast cancer.

Detailed Description

The hypothesis is that genomic profiling measured by CancerSCAN, cfDNA, Whole exome sequencing (WES), Whole transcriptome sequencing (WTS), FACS(Fluorescence-Activated Cell Sorting), cytokine and immunologic signature analysis would be helpful to find out tolerance for chemotherapy and innovate new therapeutic strategies.

Registry

clinicaltrials.gov

Start Date

September 2012

End Date

July 2019

Last Updated

9 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Samsung Medical Center

Responsible Party

Principal Investigator

Young-Hyuck Im

MD, Ph.D, Division of Hematology-Oncology

Samsung Medical Center

Eligibility Criteria

Inclusion Criteria

•Histologically or cytologically confirmed breast cancer that is either metastatic or young breast cancer(≤ 40 years of age).
•HER2 positive patient who failed HER2 target therapy including trastuzumab with feasible biopsy site.
•Triple Negative Breast Cancer patient who failed standard therapy with feasible biopsy site.
•Hormone Receptor positive patient who failed standard therapy with feasible biopsy site.
•Age ≥ 21 years
•Written informed consent